Mammary Cell News Volume 7.13 | Apr 9 2015

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Investigators confirmed that cell cycle or apoptosis responses to estrogen or tamoxifen in estrogen receptor α (ERα)-positive breast cancer cells were impaired by TGFβ receptor type 2 silencing, as was ERα phosphorylation, tamoxifen-induced transcriptional activation of TGFβ, and upregulation of the multidrug resistance protein ABCG2. [Cancer Res] Abstract

Oroxylin A Inhibits Glycolysis-Dependent Proliferation of Human Breast Cancer via Promoting SIRT3-Mediated SOD2 Transcription and HIF1α Destabilization
Scientists showed that oroxylin A inhibits glycolysis in breast cancer cells via the sirtuin 3 (SIRT3)-mediated destabilization of hypoxia-inducible factor 1α (HIF1α), which controls glycolytic gene expression. Oroxylin A promoted superoxide dismutase (SOD2) gene expression through SIRT3-regulated DNA-binding activity of FOXO3a and increases the activity of SOD2 by promoting SIRT3-mediated deacetylation. [Cell Death Dis] Full Article

CRLX101, an Investigational Camptothecin-Containing Nanoparticle-Drug Conjugate, Targets Cancer Stem Cells and Impedes Resistance to Antiangiogenic Therapy in Mouse Models of Breast Cancer
Researchers tested whether inhibiting hypoxia-inducible factor 1α (HIF-1α) can reverse the stimulatory effects of antiangiogenic-induced hypoxia on breast cancer stem cells (CSCs). Breast cancer cells grown under hypoxic conditions were treated with the dual topoisomerase-1 and HIF-1α inhibitor camptothecin and assessed for their CSC content. [Breast Cancer Res Treat] Abstract

miR-107 Down-Regulates SIAH1 Expression in Human Breast Cancer Cells and Silencing of miR-107 Inhibits Tumor Growth in a Nude Mouse Model of Triple-Negative Breast Cancer
The authors demonstrated that miR-107 directly down-regulates SIAH1 expression in human breast cancer cells. Overexpression of miR-107 reduced SIAH1 expression, promoted human breast cancer cell proliferation, colony formation, migration and invasion, and inhibited apoptosis. [Mol Carcinogen] Abstract

Aromatase Expression Increases the Survival and Malignancy of Estrogen Receptor Positive Breast Cancer Cells
Scientists showed that the aromatase expression increased when estrogen receptor alpha (ERα) positive breast cancer cells were cultured in suspension. Treatment with the aromatase substrate, testosterone, inhibited suspension culture-induced apoptosis whereas an aromatase inhibitor attenuated the effect of testosterone suggesting that suspended circulating ERα positive breast cancer cells may up-regulate intracrine estrogen activity for survival. [PLoS One] Full Article

Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas
Scientists assessed the relationship between the Cdx2 vitamin D receptor (VDR) polymorphism and the activities of VDR in human breast cancer cell lines and carcinomas breast patients. Cdx2 VDR polymorphism and antiproliferative effects of vitamin D treatment were investigated in a panel of estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. [PLoS One] Full Article

Synergistic Effect between Celecoxib and Luteolin Is Dependent on Estrogen Receptor in Human Breast Cancer Cells
Researchers compared the effects of a celecoxib and luteolin combination treatment in four different human breast cell lines and determined the mechanisms of action in vitro and in vivo. [Tumor Biol] Abstract

CLINICAL RESEARCH

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
Glembatumumab vedotin is a glycoprotein NMB (gpNMB)-specific monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin E. Researchers investigated the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression. [J Clin Oncol] Abstract | Press Release

A Multicenter Phase II Clinical Trial of Platinum Monotherapy with Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Investigators conducted a single-arm Phase II clinical trial of single-agent platinum for metastatic triple-negative breast cancer with biomarker correlates. [J Clin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Cold Spring Harbor Laboratory and North Shore-LIJ Announce Strategic Affiliation to Accelerate Benefits of Cancer Research to Patients
Cold Spring Harbor Laboratory (CSHL) and the North Shore-LIJ Health System announced a strategic affiliation to align CSHL’s world-class cancer research with North Shore-LIJ’s growing network of clinical services encompassing more than 16,000 new cancer cases annually across the New York metropolitan area. [Cold Spring Harbor Laboratory] Press Release

UNC Lineberger Sequences 10,000 Tumors as Part of National Cancer Genomics Effort
The UNC Lineberger Comprehensive Cancer Center is leading a national, multi-year, collaborative effort to characterize the genetic changes in nearly 30 cancer types. Earlier this year, UNC Lineberger hit a milestone in this effort – sequencing 10,000 samples of cancer tumor tissue. [UNC Lineberger] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Biostatistician – Molecular and Genetic Breast Cancer Epidemiology (Netherlands Cancer Institute)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Prostate Cancer and Breast Cancer (Baylor College of Medicine)

Histology Research Technician (King’s College London)

Research Technician – Breast Cancer Research (King’s College London)

Postdoctoral Position – Triple Negative Breast Cancer (King’s College London)

Postdoctoral Fellow – Breast Cancer & Stem Cell Biology (University of Cincinnati)

Senior Scientific Operations Manager – Breast Cancer Research (Institute of Cancer Research)

Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (University of Cincinnati College of Medicine)

Postdoctoral Fellow – Cancer/Breast Cancer Genomic Instability and Cell Biology (University of Queensland)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.